Finance

Lists
RVMD:NASDAQ
Revolution Medicines Inc
$186.99
-0.37%
(-0.70) 1D
$186.00
-0.53% (-0.99)
After hours
Closed: Oct 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RVMD...
Open
$187.59
High
$189.52
Low
$183.61
Mkt. cap
40.08B
Avg. vol.
2.24M
Volume
1.72M
52-wk high
$224.31
52-wk low
$53.68
EPS
-$8.83
Beta
1.40
Shares outstanding
214.34M
No. of employees
883
Open
$187.59
High
$189.52
Low
$183.61
Mkt. cap
40.08B
Avg. vol.
2.24M
Volume
1.72M
52-wk high
$224.31
52-wk low
$53.68
EPS
-$8.83
Beta
1.40
Shares outstanding
214.34M
No. of employees
883
News stories
From web sources and news partners
About Revolution Medicines Inc
CEO-
Employees883
Founded2014
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websiterevmed.com
Analyst ratings
Based on 24 analysts giving stock ratings to RVMD in the past 3 months
Strong buy
Buy
23
Hold
1
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for RVMD in the last 3 months.
Highest
Current $186.99
$320.00 (+71.13%)
Average
$257.41 (+37.66%)
Lowest
$179.00 (-4.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Yee
UBS
Buy
Reiterated
$265.00
+41.7%
10/22/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$255.00
+36.4%
10/22/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$250.00
+33.7%
10/21/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
10/21/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$264.00
+41.2%
10/19/2026
Gregory Renza
Truist Financial
Buy
Maintained
$241.00
+28.9%
10/19/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$275.00
+47.1%
10/15/2026
Unknown Analyst
William Blair
Buy
Initiated
$226.00
+20.9%
10/15/2026
Sharon Zackfia
William Blair
Buy
Initiated
$226.00
+20.9%
10/15/2026
Ami Fadia
Needham
Buy
Reiterated
$275.00
+47.1%
10/15/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$260.00
+39%
10/14/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
-
-
10/08/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$315.00
+68.5%
10/05/2026
Leah R. Cann
Brookline Capital Markets
Buy
Initiated
$318.00
+70.1%
09/28/2026
Jeffrey Walch
Bernstein
Hold
Maintained
$179.00
-4.3%
09/25/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$267.00
+42.8%
09/24/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$270.00
+44.4%
09/03/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$248.00
+32.6%
08/27/2026
Jay Olson
Oppenheimer
Buy
Maintained
$260.00
+39%
08/27/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$320.00
+71.1%
08/27/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
$240.00
+28.3%
08/27/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$280.00
+49.7%
08/27/2026
Robert Driscoll
Wedbush
Buy
Maintained
$225.00
+20.3%
08/27/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
$220.00
+17.7%
08/10/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
08/10/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
$215.00
+15%
08/05/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$210.00
+12.3%
08/06/2026
Unknown Analyst
Bernstein
Hold
Maintained
$151.00
-19.2%
06/07/2026
Michael Morris
Guggenheim
Buy
Maintained
$175.00
-6.4%
04/22/2026
Jonathan Chang
Leerink Partners
Buy
Reiterated
$147.00
-21.4%
04/13/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
-
-
03/09/2026
Next call in 10 days
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- / -$2.38
Revenue / Est. (USD)
- / 27.35M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
262.51M
294.94M
343.97M
394.92M
Cost of revenue
262.51M
294.94M
343.97M
394.92M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52.76M
66.68M
101.25M
110.21M
Operating expense
52.76M
66.68M
101.25M
110.21M
Total operating expenses
315.27M
361.63M
445.22M
505.13M
Operating income
-315.27M
-361.63M
-445.22M
-505.13M
Other non operating income
-592.00K
-12.62M
-15.90M
-151.04M
EBT including unusual items
-305.21M
-364.89M
-453.82M
-644.37M
EBT excluding unusual items
-305.21M
-364.89M
-453.82M
-644.37M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-305.21M
-364.89M
-453.82M
-644.37M
Net profit margin
-
-
-
-
Earnings per share
-1.61
-1.86
-2.29
-3.06
Interest and investment income
22.08M
21.29M
19.51M
35.58M
Interest expense
-11.43M
-11.94M
-12.20M
-23.78M
Net interest expenses
10.66M
9.36M
7.31M
11.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-313.24M
-359.39M
-442.88M
-502.68M
Gain or loss from assets sale
32.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps